CCR2 and neoplasm: Furthermore, we demonstrated that the iADCs TAK-500 and mTAK-500 induce CCR2-dependent innate and adaptive immune cell activation and prominent antitumor effect in both human cells and tumor-bearing mice, wherein CCR2 is highly expressed in intratumoral myeloid cells from human malignancies and high CCR2 is associated with local adaptive immune responses and specific clinical and molecular tumor subsets.